Single-center experience of patients with interstitial lung diseases during the early days of the COVID-19 pandemic
Copyright © 2020 The Japanese Respiratory Society. Published by Elsevier B.V. All rights reserved..
INTRODUCTION: Patients with interstitial lung diseases (ILD) can be suspected to be at risk of experiencing a rapid flare-up due to COVID-19. However, no specific data are currently available for these patients.
METHODS: We retrospectively analyzed a cohort of 401 patients with ILD and determined the proportion of patients hospitalized for proven severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and specific symptoms of COVID-19.
RESULTS: We found that 1% of patients (n = 4) were hospitalized (1 in ICU) for COVID-19. In total, 310 of the 401 patients answered the phone call. Only 33 patients (0.08%) experienced specific symptoms of SARS-CoV-2 infection.
CONCLUSION: Our study did not demonstrate any increased occurrence of severe COVID-19 in ILD patients compared to the global population. Based on our findings, we could not make any conclusion on the incidence rate of SARS-CoV-2 infection in patients with ILDs, or on the overall outcome of immunocompromised patients affected by COVID-19.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:58 |
|---|---|
| Enthalten in: |
Respiratory investigation - 58(2020), 6 vom: 01. Nov., Seite 437-439 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Guiot, J [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Completed 25.11.2021 Date Revised 25.11.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.resinv.2020.08.006 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM315488492 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM315488492 | ||
| 003 | DE-627 | ||
| 005 | 20231225155026.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.resinv.2020.08.006 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1051.xml |
| 035 | |a (DE-627)NLM315488492 | ||
| 035 | |a (NLM)32978099 | ||
| 035 | |a (PII)S2212-5345(20)30124-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Guiot, J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Single-center experience of patients with interstitial lung diseases during the early days of the COVID-19 pandemic |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.11.2021 | ||
| 500 | |a Date Revised 25.11.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 The Japanese Respiratory Society. Published by Elsevier B.V. All rights reserved. | ||
| 520 | |a INTRODUCTION: Patients with interstitial lung diseases (ILD) can be suspected to be at risk of experiencing a rapid flare-up due to COVID-19. However, no specific data are currently available for these patients | ||
| 520 | |a METHODS: We retrospectively analyzed a cohort of 401 patients with ILD and determined the proportion of patients hospitalized for proven severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and specific symptoms of COVID-19 | ||
| 520 | |a RESULTS: We found that 1% of patients (n = 4) were hospitalized (1 in ICU) for COVID-19. In total, 310 of the 401 patients answered the phone call. Only 33 patients (0.08%) experienced specific symptoms of SARS-CoV-2 infection | ||
| 520 | |a CONCLUSION: Our study did not demonstrate any increased occurrence of severe COVID-19 in ILD patients compared to the global population. Based on our findings, we could not make any conclusion on the incidence rate of SARS-CoV-2 infection in patients with ILDs, or on the overall outcome of immunocompromised patients affected by COVID-19 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Clinical epidemiology | |
| 650 | 4 | |a Interstitial lung diseases | |
| 650 | 4 | |a Lung fibrosis | |
| 700 | 1 | |a Henket, M |e verfasserin |4 aut | |
| 700 | 1 | |a Frix, A N |e verfasserin |4 aut | |
| 700 | 1 | |a Delvaux, M |e verfasserin |4 aut | |
| 700 | 1 | |a Denis, A |e verfasserin |4 aut | |
| 700 | 1 | |a Giltay, L |e verfasserin |4 aut | |
| 700 | 1 | |a Thys, M |e verfasserin |4 aut | |
| 700 | 1 | |a Gester, F |e verfasserin |4 aut | |
| 700 | 1 | |a Moutschen, M |e verfasserin |4 aut | |
| 700 | 1 | |a Corhay, J L |e verfasserin |4 aut | |
| 700 | 1 | |a Louis, R |e verfasserin |4 aut | |
| 700 | 0 | |a COVID-19 clinical investigators of the CHU de Liège |e verfasserin |4 aut | |
| 700 | 1 | |a Ancion, A |e investigator |4 oth | |
| 700 | 1 | |a Bouquegneau, A |e investigator |4 oth | |
| 700 | 1 | |a Bovy, C |e investigator |4 oth | |
| 700 | 1 | |a Darcis, G |e investigator |4 oth | |
| 700 | 1 | |a Defraigne, J O |e investigator |4 oth | |
| 700 | 1 | |a Duysinx, B |e investigator |4 oth | |
| 700 | 1 | |a Ghuysen, A |e investigator |4 oth | |
| 700 | 1 | |a Gilbert, A |e investigator |4 oth | |
| 700 | 1 | |a Heinen, V |e investigator |4 oth | |
| 700 | 1 | |a Lambermont, B |e investigator |4 oth | |
| 700 | 1 | |a Malaise, O |e investigator |4 oth | |
| 700 | 1 | |a Martin, M |e investigator |4 oth | |
| 700 | 1 | |a Misset, B |e investigator |4 oth | |
| 700 | 1 | |a Moutschen, M |e investigator |4 oth | |
| 700 | 1 | |a Nguyen Dang, D |e investigator |4 oth | |
| 700 | 1 | |a Piazza, J |e investigator |4 oth | |
| 700 | 1 | |a Szecel, J |e investigator |4 oth | |
| 700 | 1 | |a Vaillant, F |e investigator |4 oth | |
| 700 | 1 | |a Van Cauwenberge, H |e investigator |4 oth | |
| 700 | 1 | |a Von Frenckell, C |e investigator |4 oth | |
| 700 | 1 | |a Vroonen, L |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Respiratory investigation |d 2012 |g 58(2020), 6 vom: 01. Nov., Seite 437-439 |w (DE-627)NLM217493343 |x 2212-5353 |7 nnns |
| 773 | 1 | 8 | |g volume:58 |g year:2020 |g number:6 |g day:01 |g month:11 |g pages:437-439 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.resinv.2020.08.006 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 58 |j 2020 |e 6 |b 01 |c 11 |h 437-439 | ||